Skip to main content
SpringerLink
Log in

Weekly low dose doxorubicin monotherapy in metastatic breast cancer resistant to previous hormonal and cytostatic treatment

  • Report
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Weekly low dose doxorubicin monotherapy was evaluated in heavily pretreated patients with metastatic breast cancer. 19 patients received 8–12 mg/m2 doxorubicin/week for a treatment period of up to 7 months until a progression of the disease occurred (mean number of weekly courses 15 ± 8). In 2 of 17 evaluable patients, an objective response with a duration of 3+ and 5 months respectively was achieved. In 9 patients a stabilisation of the disease was observed (mean duration of DS 4 mos ±2), whereas the disease progressed in 6. The tolerance for this regimen was remarkable, with neither serious acute toxocity nor any signs of congestive cardiomyopathy even in those patients who were treated beyond a cumulative dose of 450 mg/m2. Weekly low dose doxorubicin monotherapy shows modest activity, but is devoid of severe toxicity in heavily pretreated patients with metastatic breast cancer. An increase in the therapeutic index was not observed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Harvey HA, Santen RJ, Osterman J, Samojlik E, White DS, Lipton A: A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminogluthetimide in advanced breast cancer. Cancer 43: 2207–2214, 1979

    PubMed  Google Scholar 

  2. Mouridsen HT, Palshof T, Patterson J, Battersby L: Tamoxifen — a review of its efficacy in advanced breast cancer. Cancer Treat Rev 5:131–139, 1978

    PubMed  Google Scholar 

  3. De Lena M,Brambilla C, Valagussa P, Bonadonna G: High-dose medroxyprogesterone acetate in breast cancer resistant to endocrine and cytotoxic therapy. Cancer Chemother Pharmacol 2:175–180, 1979

    PubMed  Google Scholar 

  4. Pannuti F, Martoni A, Dimarco AR, Piana E, Saccani F, Brecchi G, Mattioli G, Barbanti F, Marra GA, Persiani W, Cacciari L, Spagnolo F, Palenzona D, Rocchetta G: Prospective randomized clinical trial of two different high dosages of medroxyprogesterone acetate (MAP) in the treatment of metastatic breast cancer. Eur J Cancer 15:593–601, 1979

    PubMed  Google Scholar 

  5. Henderson IC, Canellos GP: Cancer of the breast: the past decade. N Engl J Med 302:17–30, 1980

    PubMed  Google Scholar 

  6. Carter SK: Integration of chemotherapy into combined modality treatment of solid tumors. VII: adenocarcinoma of the breast. Cancer Treat Rev 3:141–174, 1976

    PubMed  Google Scholar 

  7. Weiss AJ, Manthel RW: Experience with the use of adriamycin in combination with other anticancer agents using a weekly schedule with particular reference to a lack of cardiotoxicity. Cancer 40:2046–2052, 1977

    PubMed  Google Scholar 

  8. Carter SK: Adriamycin, a review. J Natl Cancer Inst 35: 1265–1268, 1975

    Google Scholar 

  9. Chlebowsky RT, Paroly WS, Pugh RP, Hueser J, Jacobs EM, Pajak TF, Bateman JR: Adriamycin given as a weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. Cancer Treat Rep 64:47–51, 1980

    PubMed  Google Scholar 

  10. Weiss AJ, Metter GE, Fletcher WS: Studies on adriamycin using a weekly regimen demonstrating its clinical effectiveness and lack of cardiac toxicity. Cancer Treat Rep 60:813–822, 1976

    PubMed  Google Scholar 

  11. Mattson W, Borgstroem S, Landberg T: A weekly schedule without a loading course: clinically effective with reduced incidence of cardiotoxicity. Clin Ther 5:193–203, 1982

    PubMed  Google Scholar 

  12. Hayward JL, Carbone PP, Henson JC, Kumacka S, Segaloff A, Rubens RD: Assessment of response to therapy in advanced breast cancer. Br J Cancer 13:89–94, 1977

    Google Scholar 

  13. Von Hoff DD, Layard MW, Basa P: Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91:710–717, 1979

    PubMed  Google Scholar 

  14. Lloyd RE, Jones SE, Salmon SE: Comparative trial of low dose adriamycin plus cyclophosphamide with or without additive hormonal therapy in advanced breast cancer. Cancer 43:60–65, 1979

    PubMed  Google Scholar 

  15. Gottlieb JA, Rivkin SE, Spigel SC, Hoogstraten B, O'Bryan RM, Delaney FC, Singhakowinta A: Superiority of adriamycin over oral nitrosureas in patients with advanced breast carcinoma. Cancer 33:519–526, 1974

    PubMed  Google Scholar 

  16. Hoogstraten B, George SL, Samal B, Rivkin SE, Costanzi JJ, Bonnet JD, Thispen T, Braine H: Combination chemotherapy and adriamycin in patients with advanced breast cancer — a South West Oncology Group study. Cancer 38:13–20, 1976

    PubMed  Google Scholar 

  17. O'Bryan RM, Baker LH, Gottlieb JE, Rivkin SE, Balcerzac SP, Grumet GN, Salmon SE, Moon TE, Hoogstraten B: Dose response evaluation of adriamycin in human neoplasia. Cancer 39:1940–1948, 1977

    Google Scholar 

  18. Tormey DC: Adriamycin (NSC-123127) in breast cancer: an overview of studies. Cancer Chemother Rep 6(3):319–327, 1975

    Google Scholar 

  19. Nash CH, Jones SE, Moon TE, Davis SL, Salmon SE: Prediction of outcome in metastatic breast cancer treated with adriamycin combination chemotherapy. Cancer 46: 2380–2388, 1980

    PubMed  Google Scholar 

  20. Ahmann DL, Bisner HF, Egan RT, Edmonson JH, Hahn RG: Controlled evaluation of adriamycin (NSC-123127) in patients with disseminated breast cancer. Cancer Chemother Rep 58:877–882, 1974

    PubMed  Google Scholar 

  21. Creech RH, Catalano RB, Shah MK: An effective lowdose adriamycin regimen as secondary chemotherapy for metastatic breast cancer patients. Cancer 46:433–437, 1980

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine II, University of Vienna, Garnisongasse 13, A-1090, Vienna, Austria

    Werner Scheithauer, Christoph Zielinksi & Heinz Ludwig

Authors
  1. Werner Scheithauer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Christoph Zielinksi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Heinz Ludwig
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Scheithauer, W., Zielinksi, C. & Ludwig, H. Weekly low dose doxorubicin monotherapy in metastatic breast cancer resistant to previous hormonal and cytostatic treatment. Breast Cancer Res Tr 6, 89–93 (1985). https://doi.org/10.1007/BF01806014

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01806014

Key words

Search

Navigation